Leo Pharma closely followed by Pfizer and Abbvie with FDA atopic eczema approvals

Only a few weeks after the FDA approved Leo Pharma's Adbry for atopic eczema, Pfizer and Abbvie are cleared with drugs in the same indication.

Photo: Leo Pharma / PR

A race has broken out on the atopic eczema market in the US. While Danish pharmaceutical firm Leo Pharma leads among three new contenders, having had its candidate approved by the US Food and Drug Administration (FDA) around New Year's, it will soon be followed by two other treatments.

The FDA has just approved therapies from two large US-based companies, Abbvie and Pfizer, for patients aged 12 and up with moderate-to-severe atopic eczema, also known as atopic dermatitis. A total of three firms are thus ready to fight it out for market shares of the enormous disease area, where only one biologic drug, French Sanofi's Dupixent, has been available until now.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Analyst predicts slow start for Leo Pharma's Adtralza in UK

The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.

Further reading

Related articles

Latest news

See all jobs